AZ's immunotherapy combo fails in phase 3 lung cancer trial

AstraZeneca’s Imfinzi plus standard chemo improves overall survival in untreated extensive-stage small cell lung cancer – but a combination therapy involving another immunotherapy does not,

Merck, Pfizer’s Bavencio flunks head and neck cancer trial

AZ's cediranib falls short again in ovarian cancer combinati...

AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it did not improve survival compared with chemotherapy in advanced ovarian cancer, in

Amgen/Allergan's rituximab biosimilar could be $4bn blockbus...

Ten drugs filed with regulators have potential to become billion-sellers by 2025 according to new research, with a near-copy of Roche’s rituximab from Amgen and Allergan showing the mo

Janssen antibody could be lung cancer breakthrough

The FDA thinks a dual-target antibody from Janssen could set new standards in treatment for certain patients with lung cancer, whose disease has progressed after chemotherapy and are unlike

Takeda's Ninlaro falls short in first line multiple myeloma

Takeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid and chemo in newly diagnosed multiple myeloma.